

Dicerna Pharmaceuticals Inc
Form 8-K
April 12, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 12, 2017 (April 11, 2017)

DICERNA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction

of incorporation)

001-36281
(Commission

File Number)
87 Cambridgepark Drive

20-5993609
(I.R.S. Employer

Identification Number)

Edgar Filing: Dicerna Pharmaceuticals Inc - Form 8-K

Cambridge, MA 02140

(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (617) 621-8097

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2 below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4c)

Item 8.01 Other Events.

On April 11, 2017, Dicerna Pharmaceuticals, Inc., a Delaware corporation (the Company), closed its previously announced stock purchase transaction for the sale of redeemable convertible preferred stock (Preferred Stock) to a syndicate of current and new investors led by Bain Capital Life Sciences Fund, L.P., under which the Company received gross proceeds of \$70.0 million. At the closing, the Company issued 700,000 shares of Preferred Stock which are convertible into common shares at an initial conversion price of \$3.19 per share.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 12, 2017

DICERNA PHARMACEUTICALS, INC.

By: /s/ John B. Green
John B. Green

Chief Financial Officer